纳比洛尔含或分散片的制备与研究

Rédai Emőke, Péter Csilla, Kovács Béla, Ciurba Adriana, Todoran Nicoleta, Antonoaeae Paula, Vlad Robert-Alexandru, Sipos Emese
{"title":"纳比洛尔含或分散片的制备与研究","authors":"Rédai Emőke, Péter Csilla, Kovács Béla, Ciurba Adriana, Todoran Nicoleta, Antonoaeae Paula, Vlad Robert-Alexandru, Sipos Emese","doi":"10.2478/orvtudert-2020-0001","DOIUrl":null,"url":null,"abstract":"Abstract In case of chronic diseases patient compliance to long-term treatment is of utmost importance. Patient compliance is generally higher for pharmaceutical forms dispersing in the oral cavity. One classic example for long-term therapy is hypertension. The aim of this study is to obtain nebivolol hydrochloride containing orally disintegrating tablets. As manufacturing technology, direct compression was chosen and rapid disintegration was aimed to be achieved using superdisintegrants. Various formulae have been developed, containing Kollidon and Polyplasdone in different concentrations, and the obtained dry powder mixtures were studied for their rheological properties. Afterwards these mixtures were compressed to obtain tablets. Active ingredient was embedded in the formulations with the shortest disintegration times (15 and 18 seconds) and the obtained tablets were studied for disintegration time, mechanical resistance, drug content and dissolution. Our results show that the pharmaceutical formulations containing Kollidon CL 5% or Polyplasdone XL 3% fulfill the requirements of orally disintegrating tablets, having a disintegration time under 3 minutes, proper mechanical resistance (greater than 80N) and the dissolution of the active ingredient is greater than 80% in 30 minutes.","PeriodicalId":9334,"journal":{"name":"Bulletin of Medical Sciences","volume":"19 1","pages":"27 - 32"},"PeriodicalIF":0.0000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Formulation and study of nebivolol containing orodispersable tablets\",\"authors\":\"Rédai Emőke, Péter Csilla, Kovács Béla, Ciurba Adriana, Todoran Nicoleta, Antonoaeae Paula, Vlad Robert-Alexandru, Sipos Emese\",\"doi\":\"10.2478/orvtudert-2020-0001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract In case of chronic diseases patient compliance to long-term treatment is of utmost importance. Patient compliance is generally higher for pharmaceutical forms dispersing in the oral cavity. One classic example for long-term therapy is hypertension. The aim of this study is to obtain nebivolol hydrochloride containing orally disintegrating tablets. As manufacturing technology, direct compression was chosen and rapid disintegration was aimed to be achieved using superdisintegrants. Various formulae have been developed, containing Kollidon and Polyplasdone in different concentrations, and the obtained dry powder mixtures were studied for their rheological properties. Afterwards these mixtures were compressed to obtain tablets. Active ingredient was embedded in the formulations with the shortest disintegration times (15 and 18 seconds) and the obtained tablets were studied for disintegration time, mechanical resistance, drug content and dissolution. Our results show that the pharmaceutical formulations containing Kollidon CL 5% or Polyplasdone XL 3% fulfill the requirements of orally disintegrating tablets, having a disintegration time under 3 minutes, proper mechanical resistance (greater than 80N) and the dissolution of the active ingredient is greater than 80% in 30 minutes.\",\"PeriodicalId\":9334,\"journal\":{\"name\":\"Bulletin of Medical Sciences\",\"volume\":\"19 1\",\"pages\":\"27 - 32\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin of Medical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/orvtudert-2020-0001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/orvtudert-2020-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

对于慢性疾病患者而言,长期治疗的依从性至关重要。患者的依从性通常较高的药物形式分散在口腔。长期治疗的一个典型例子是高血压。本研究的目的是制备盐酸奈比洛尔口腔崩解片。制备工艺选择直接压缩,采用超崩解剂实现快速崩解。不同浓度的Kollidon和Polyplasdone组成了不同的配方,并研究了所得到的干粉混合物的流变特性。然后将这些混合物压缩成片剂。以最短崩解时间(15秒和18秒)包埋有效成分,考察崩解时间、机械阻力、药物含量和溶出度。结果表明,含5% Kollidon CL或3% Polyplasdone XL的制剂均满足口腔崩解片的要求,崩解时间小于3 min,机械阻力适宜(大于80N), 30 min内有效成分溶出度大于80%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Formulation and study of nebivolol containing orodispersable tablets
Abstract In case of chronic diseases patient compliance to long-term treatment is of utmost importance. Patient compliance is generally higher for pharmaceutical forms dispersing in the oral cavity. One classic example for long-term therapy is hypertension. The aim of this study is to obtain nebivolol hydrochloride containing orally disintegrating tablets. As manufacturing technology, direct compression was chosen and rapid disintegration was aimed to be achieved using superdisintegrants. Various formulae have been developed, containing Kollidon and Polyplasdone in different concentrations, and the obtained dry powder mixtures were studied for their rheological properties. Afterwards these mixtures were compressed to obtain tablets. Active ingredient was embedded in the formulations with the shortest disintegration times (15 and 18 seconds) and the obtained tablets were studied for disintegration time, mechanical resistance, drug content and dissolution. Our results show that the pharmaceutical formulations containing Kollidon CL 5% or Polyplasdone XL 3% fulfill the requirements of orally disintegrating tablets, having a disintegration time under 3 minutes, proper mechanical resistance (greater than 80N) and the dissolution of the active ingredient is greater than 80% in 30 minutes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Quality by design-based method development for the determination of related substances of ezetimibe by high performance liquid chromatography Determination of the sun protection factor of sunscreens Alzheimer’s disease beyond the amyloid accumulation Radioactive background radiation measurement in Mureş county Study of pulmonary complications in patients referred to the intensive care unit
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1